Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant apatinib plus chemotherapy for head and neck squamous cell carcinoma
ChiCTR2100049298Phase 4Recruiting
- Sponsor
- The Second Affiliated Hospital of Anhui Medical University
- Start
- Jul 2021
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in head and neck squamous cell carcinoma (HNSCC), sponsored by The Second Affiliated Hospital of Anhui Medical University. Primary endpoint: pathological response rate. Started Jul 2021; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2100049298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049298.